The brief

Analyst view

• Founded 2023 by Baker (UW protein design) and Tessier-Lavigne (Genentech CSO). $1B+ funding from ARCH, Foresite and others.
• X-Design: AI designs novel proteins and antibodies from scratch for targets resistant to traditional therapeutics.
• Platform integrates X-Cell (target discovery), X-Scientist (agentic AI), and X-Automate (robotics) for accelerated drug development.

Technical approach

As reported

Design

X-Design generative models

RFdiffusion and RFantibody design novel proteins and antibodies from scratch.

Target identification

X-Cell disease mechanism discovery

AI models identify actual disease targets and mechanisms, not just statistical correlations, to focus drug development on root causes.

Patient matching

X-Patient population identification

Identifies patients most likely to respond to designed therapeutics, improving trial design and commercial viability.

Lab automation

X-Automate experimental pipeline

Robot arms and lab automation enable high-throughput synthesis and screening, compressing the cycle from design to validation.

Show all 4